TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials
source: pixabay.com

TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials

TrialJectory is an organization working to match bladder, breast, colorectal, melanoma, myelodysplastic syndromes (MDS), and other cancer patients with the clinical trial that is right for them. They have successfully raised…

Continue Reading TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials
Facebook Takes Action on Groups Promoting Black Salve, an Ineffective and Dangerous Cancer Treatment
source: pixabay.com

Facebook Takes Action on Groups Promoting Black Salve, an Ineffective and Dangerous Cancer Treatment

According to a story from Buzzfeed News, social media giant Facebook has finally taken action against groups on the site that promote the use of black salve, an alternative treatment…

Continue Reading Facebook Takes Action on Groups Promoting Black Salve, an Ineffective and Dangerous Cancer Treatment
Scientists Find That Rubella and Certain Cancers Have the Same Mutation Mechanisms
source: pixabay.com

Scientists Find That Rubella and Certain Cancers Have the Same Mutation Mechanisms

By Danielle Bradshaw from In The Cloud Copy Scientific teams at the Centers for Disease Control (CDC), the National Institute of Environmental Health Sciences (NIEHS), and other research centers have…

Continue Reading Scientists Find That Rubella and Certain Cancers Have the Same Mutation Mechanisms

Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society

  When the Leukemia & Lymphoma Society (LLS) was founded in 1949 by a family in memory of their sixteen-year-old son, cancer was considered a hopeless condition. As noted recently…

Continue Reading Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society
IYCMI: CALQUENCE Has Received US FDA Approval to Benefit Adults with CLL
source: pixabay.com

IYCMI: CALQUENCE Has Received US FDA Approval to Benefit Adults with CLL

  A recent article in BioPortfolio carried AstraZeneca’s announcement of the FDA’s approval of CALQUENCE® (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The approval…

Continue Reading IYCMI: CALQUENCE Has Received US FDA Approval to Benefit Adults with CLL
First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
source: pixabay.com

First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial

According to a story from Myeloma Research News, the first patient has been dosed with an experimental allogeneic (donor derived) CAR-T cell therapy called UCARTCS1 as part of a phase…

Continue Reading First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
The FDA Approves New Treatment for Chronic Lymphocytic Leukemia Under an International Program
source: pixabay.com

The FDA Approves New Treatment for Chronic Lymphocytic Leukemia Under an International Program

According to a story from PR Newswire, the US Food and Drug Administration (FDA) has recently granted supplemental approval to the drug acalabrutinib (marketed as Calquence) as a treatment for…

Continue Reading The FDA Approves New Treatment for Chronic Lymphocytic Leukemia Under an International Program
Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma
ArtTower / Pixabay

Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma

According to a story from the Malvern Daily Record, the biotechnology company Exelixis, Inc. has recently announced that its partner company Ipsen BioPharmaceuticals Canada Inc. has had its drug cabozantinib…

Continue Reading Health Canada Approves Cabometyx for Previously Treated Hepatocellular Carcinoma

Phase 3 CONDOR Study of PYL: The Potential To Improve The Outcome of Recurrent Prostate Cancer

490 words 8% vs 1306 words 3% According to a recent Globe Newswire release, Progenics Pharmaceuticals, an oncology company that specializes in artificial intelligence and targeted therapies, announced results for its Phase…

Continue Reading Phase 3 CONDOR Study of PYL: The Potential To Improve The Outcome of Recurrent Prostate Cancer

GRYT Health’s Annual Global Virtual Cancer Conference

  • Post author:
  • Post category:

The 2019 Global Virtual Cancer Conference "Everyone's Experience Matters" Cancer treatment choices are most often a doctor-directed affair with only minimal input from caregivers and patients. The Global Virtual Cancer…

Continue Reading GRYT Health’s Annual Global Virtual Cancer Conference